MetaCap

Allogene Therapeutics (ALLO) vs Lexeo Therapeutics (LXEO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Allogene Therapeutics (ALLO) has outperformed Lexeo Therapeutics (LXEO) over the past year, losing 49.0% versus a loss of 67.3%. Lexeo Therapeutics is the larger company by market cap ($245.1 million vs $217.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALLO-48.97%LXEO-67.33%
+160%+39%-82%
Nov 21, 20251 yearNov 20, 2026
ALLO-82.07%LXEO-70.55%
+83%-3%-90%
Oct 30, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALLO versus LXEO key metrics
MetricALLOLXEO
Share price$0.6277$2.96
Market cap$217.48M$245.05M
1-day change-5.88%+0.34%
YTD return-54.18%-70.19%
1-year return-48.97%-67.33%
5-year return-96.51%—
EPS (TTM)$-0.61$-1.13
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-190.89M$-100.00M
52-week high$4.46$10.99
52-week low$0.6192$2.55
Distance from 52-week high-85.93%-73.07%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1333.81%+748.31%
Average volume7.69M1.98M
Shares outstanding346.47M82.79M
Employees15068
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ALLO has outperformed LXEO by 18.4 percentage points over the past year.

About Allogene Therapeutics

ALLO stock →

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees

About Lexeo Therapeutics

LXEO stock →

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 68 employees

ALLO vs LXEO FAQ

Which is bigger, Allogene Therapeutics or Lexeo Therapeutics?

Lexeo Therapeutics (LXEO) is larger, with a market capitalization of $245.05M compared with $217.48M for Allogene Therapeutics (ALLO).

Which stock has performed better over the past year, ALLO or LXEO?

ALLO returned -48.97% over the past 12 months, compared with -67.33% for LXEO (price return, excluding dividends). Past performance does not predict future results.

Are Allogene Therapeutics and Lexeo Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons